ClearPoint Neuro financials
$11.77−23.12%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 |
|---|---|---|---|---|---|---|
| Revenue | $37.0M | $31.4M | $24.0M | $20.6M | $16.3M | $12.8M |
| Gross profit | $22.7M | $19.1M | $13.6M | $13.5M | $11.1M | $9.1M |
| Gross margin | 61.4% | 60.9% | 56.8% | 65.8% | 68.2% | 71.1% |
| Operating income | -$24.2M | -$19.7M | -$22.4M | -$16.3M | -$13.4M | -$6.2M |
| Net income | -$25.5M | -$18.9M | -$22.1M | -$16.4M | -$14.4M | -$6.8M |
| Net margin | −69.1% | −60.3% | −92.2% | −80.0% | −88.4% | −52.9% |
| Diluted EPS | $-0.90 | $-0.70 | $-0.90 | $-0.68 | $-0.69 | $-0.43 |
| EBITDA | -$21.9M | -$17.8M | -$22.4M | -$15.6M | -$12.7M | -$5.7M |
| Operating cash flow | -$23.9M | -$8.9M | -$13.7M | -$16.2M | -$12.7M | -$7.8M |
| Free cash flow | -$24.4M | -$9.2M | -$14.4M | -$16.4M | -$12.9M | -$7.8M |
| Diluted shares | 28.3M | 27.0M | 24.6M | 24.2M | 20.7M | 15.8M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $45.9M | $20.1M | $23.1M | $27.6M | $54.1M | $20.1M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $9.9M | $0.00 | — |
| Total debt | $49.1M | $0.00 | $9.9M | $9.9M | $9.8M | $21.3M |
| Total assets | $97.7M | $39.2M | $42.7M | $55.5M | $65.6M | $29.5M |
| Total liabilities | $69.7M | $13.8M | $21.5M | $18.6M | $16.8M | $27.1M |
| Shareholders' equity | $28.0M | $25.4M | $21.2M | $36.9M | $48.8M | $2.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology